David Risinger
Stock Analyst at Leerink Partners
(4.57)
# 219
Out of 5,170 analysts
179
Total ratings
67.68%
Success rate
14.77%
Average return
Main Sectors:
Stocks Rated by David Risinger
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| ORKA Oruka Therapeutics | Maintains: Outperform | $58 → $86 | $38.82 | +121.54% | 3 | Mar 16, 2026 | |
| AMGN Amgen | Maintains: Outperform | $305 → $355 | $349.92 | +1.45% | 6 | Feb 4, 2026 | |
| BMY Bristol-Myers Squibb Company | Maintains: Outperform | $54 → $60 | $58.11 | +3.25% | 5 | Jan 13, 2026 | |
| VRTX Vertex Pharmaceuticals | Maintains: Outperform | $456 → $525 | $458.05 | +14.62% | 6 | Dec 29, 2025 | |
| ROIV Roivant Sciences | Maintains: Outperform | $29 → $32 | $27.80 | +15.11% | 6 | Dec 15, 2025 | |
| XOMA XOMA Royalty | Maintains: Outperform | $58 → $45 | $28.76 | +56.47% | 1 | Dec 11, 2025 | |
| LLY Eli Lilly and Company | Upgrades: Outperform | $886 → $1,104 | $917.50 | +20.33% | 17 | Nov 10, 2025 | |
| IMA ImageneBio | Initiates: Outperform | $30 | $5.97 | +402.51% | 1 | Oct 24, 2025 | |
| HALO Halozyme Therapeutics | Upgrades: Market Perform | $70 | $63.27 | +10.64% | 4 | Oct 14, 2025 | |
| JNJ Johnson & Johnson | Downgrades: Market Perform | $169 → $153 | $237.60 | -35.61% | 4 | May 13, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Outperform | $762 → $834 | $737.45 | +13.09% | 9 | Feb 5, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Outperform | $206 | $206.23 | -0.11% | 7 | Nov 22, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $49 → $69 | $30.83 | +123.81% | 2 | Nov 11, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $16 | $14.91 | +7.31% | 1 | Oct 24, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $106 → $153 | $53.98 | +183.44% | 2 | Sep 3, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Market Perform | $15 → $10 | $14.01 | -28.62% | 3 | Aug 6, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $47 | $64.72 | -27.38% | 1 | Apr 16, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $6 → $11 | $28.34 | -61.19% | 2 | Aug 15, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Market Perform | $81 → $91 | $141.11 | -35.51% | 3 | Feb 3, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Market Perform | $49 → $48 | $27.41 | +75.12% | 14 | Feb 1, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $35 → $37 | $6.27 | +490.11% | 2 | Feb 22, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $162 → $176 | $181.80 | -3.19% | 3 | Apr 1, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $18 → $16 | $13.50 | +18.52% | 1 | Mar 10, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $53 → $45 | $9.65 | +366.32% | 17 | Mar 5, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $22 → $35 | $5.03 | +595.83% | 4 | Feb 26, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $31 → $41 | $25.12 | +63.22% | 5 | Nov 24, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $167 → $174 | $115.99 | +50.01% | 9 | Nov 13, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Equal-Weight | $51 | $45.53 | +12.01% | 1 | Jul 13, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Underweight | $13 → $8 | $29.44 | -72.83% | 19 | Apr 2, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $97 → $89 | $114.20 | -22.07% | 8 | Apr 2, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $5 → $3 | $12.34 | -75.69% | 4 | Apr 2, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $20 → $16 | $28.40 | -43.66% | 9 | Apr 2, 2020 |
Oruka Therapeutics
Mar 16, 2026
Maintains: Outperform
Price Target: $58 → $86
Current: $38.82
Upside: +121.54%
Amgen
Feb 4, 2026
Maintains: Outperform
Price Target: $305 → $355
Current: $349.92
Upside: +1.45%
Bristol-Myers Squibb Company
Jan 13, 2026
Maintains: Outperform
Price Target: $54 → $60
Current: $58.11
Upside: +3.25%
Vertex Pharmaceuticals
Dec 29, 2025
Maintains: Outperform
Price Target: $456 → $525
Current: $458.05
Upside: +14.62%
Roivant Sciences
Dec 15, 2025
Maintains: Outperform
Price Target: $29 → $32
Current: $27.80
Upside: +15.11%
XOMA Royalty
Dec 11, 2025
Maintains: Outperform
Price Target: $58 → $45
Current: $28.76
Upside: +56.47%
Eli Lilly and Company
Nov 10, 2025
Upgrades: Outperform
Price Target: $886 → $1,104
Current: $917.50
Upside: +20.33%
ImageneBio
Oct 24, 2025
Initiates: Outperform
Price Target: $30
Current: $5.97
Upside: +402.51%
Halozyme Therapeutics
Oct 14, 2025
Upgrades: Market Perform
Price Target: $70
Current: $63.27
Upside: +10.64%
Johnson & Johnson
May 13, 2025
Downgrades: Market Perform
Price Target: $169 → $153
Current: $237.60
Upside: -35.61%
Feb 5, 2025
Upgrades: Outperform
Price Target: $762 → $834
Current: $737.45
Upside: +13.09%
Nov 22, 2024
Upgrades: Outperform
Price Target: $206
Current: $206.23
Upside: -0.11%
Nov 11, 2024
Maintains: Outperform
Price Target: $49 → $69
Current: $30.83
Upside: +123.81%
Oct 24, 2024
Initiates: Outperform
Price Target: $16
Current: $14.91
Upside: +7.31%
Sep 3, 2024
Maintains: Outperform
Price Target: $106 → $153
Current: $53.98
Upside: +183.44%
Aug 6, 2024
Downgrades: Market Perform
Price Target: $15 → $10
Current: $14.01
Upside: -28.62%
Apr 16, 2024
Initiates: Outperform
Price Target: $47
Current: $64.72
Upside: -27.38%
Aug 15, 2023
Maintains: Outperform
Price Target: $6 → $11
Current: $28.34
Upside: -61.19%
Feb 3, 2023
Maintains: Market Perform
Price Target: $81 → $91
Current: $141.11
Upside: -35.51%
Feb 1, 2023
Maintains: Market Perform
Price Target: $49 → $48
Current: $27.41
Upside: +75.12%
Feb 22, 2022
Maintains: Equal-Weight
Price Target: $35 → $37
Current: $6.27
Upside: +490.11%
Apr 1, 2021
Maintains: Equal-Weight
Price Target: $162 → $176
Current: $181.80
Upside: -3.19%
Mar 10, 2021
Maintains: Equal-Weight
Price Target: $18 → $16
Current: $13.50
Upside: +18.52%
Mar 5, 2021
Maintains: Equal-Weight
Price Target: $53 → $45
Current: $9.65
Upside: +366.32%
Feb 26, 2021
Maintains: Equal-Weight
Price Target: $22 → $35
Current: $5.03
Upside: +595.83%
Nov 24, 2020
Maintains: Overweight
Price Target: $31 → $41
Current: $25.12
Upside: +63.22%
Nov 13, 2020
Maintains: Equal-Weight
Price Target: $167 → $174
Current: $115.99
Upside: +50.01%
Jul 13, 2020
Initiates: Equal-Weight
Price Target: $51
Current: $45.53
Upside: +12.01%
Apr 2, 2020
Maintains: Underweight
Price Target: $13 → $8
Current: $29.44
Upside: -72.83%
Apr 2, 2020
Maintains: Overweight
Price Target: $97 → $89
Current: $114.20
Upside: -22.07%
Apr 2, 2020
Maintains: Equal-Weight
Price Target: $5 → $3
Current: $12.34
Upside: -75.69%
Apr 2, 2020
Maintains: Equal-Weight
Price Target: $20 → $16
Current: $28.40
Upside: -43.66%